Related Experiment Video
Updated: Aug 30, 2026
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
[Inhibition of MCP-1 mRNA expression by propylene glycol mannate sulfate in hyperlipidemic rat aorta]
Yan Gao1, Wen-gong Yu, Feng Han
1Institute of Marine Drugs and Foods, Ocean University of China, Qingdao 266003, China.
Aim:
To study the effects of prophylene glycol mannate sulfate (PGMS) on monocyte chemoattractant protein-1 (MCP-1) mRNA expression in hyperlipidemic rat aorta and to clarify the molecular mechanism of PGMS for the prevention of atherosclerosis.
Methods:
PGMS (37.8 and 75.6 mg.kg-1.d-1, ig) or PGMS (37.8 and 75.6 mg.kg-1.d-1, ig) combined with diethyldithiocarbamate (DDC, an inhibitor of SOD, 200 mg.kg-1 every three days, i.p.) were given to hyperlipidemic rats for three weeks. The MDA content and SOD activity were determined after 12 h of starvation, and MCP-1 mRNA expression in aorta was detected by reverse transcription-polymerase chain reaction (RT-PCR).
Results:
There was significant decrease (29.46% or 58.40)% of MCP-1 mRNA expression in aortic after the therapy. The SOD activity increased markedly and the MDA content decreased at the same time. After treatment with DDC, the SOD activity was inhibited and the MDA content increased, but with no significant effect on MCP-1 mRNA expression.
Conclusion:
PGMS inhibited MCP-1 mRNA expression with no relation to its effect on decreasing MDA content.
Insights
Propylene glycol mannate sulfate (PGMS) significantly reduced monocyte chemoattractant protein-1 (MCP-1) mRNA expression in hyperlipidemic rat aortas. This suggests PGMS may prevent atherosclerosis by modulating inflammatory gene expression.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Context:
- Hyperlipidemia is a major risk factor for atherosclerosis.
- Monocyte chemoattractant protein-1 (MCP-1) plays a critical role in the inflammatory processes of atherosclerosis.
- Propylene glycol mannate sulfate (PGMS) is being investigated for its potential therapeutic effects.
Purpose:
- To investigate the effect of PGMS on MCP-1 mRNA expression in hyperlipidemic rat aortas.
- To elucidate the molecular mechanism underlying PGMS's potential anti-atherosclerotic properties.
Summary:
- Hyperlipidemic rats were treated with PGMS (37.8 and 75.6 mg.kg-1.d-1) for three weeks.
- Reverse transcription-polymerase chain reaction (RT-PCR) was used to measure MCP-1 mRNA expression.
- PGMS treatment led to a significant decrease in MCP-1 mRNA expression, accompanied by increased superoxide dismutase (SOD) activity and decreased malondialdehyde (MDA) content.
Impact:
- PGMS effectively inhibits MCP-1 mRNA expression in hyperlipidemic rat aortas.
- The anti-atherosclerotic effect of PGMS is independent of its impact on MDA content.
- Findings suggest PGMS as a potential therapeutic agent for preventing atherosclerosis by targeting inflammatory pathways.